JOHN SIMARD

President and CEO

John Simard founded XBiotech Inc. in 2005. Simard is inventor of over 300 issued and pending patents on methods and compositions relating to the identification of cancer antigens, immunotherapies for cancer and infectious disease, identifying and cloning human antibodies. John Simard founded XBiotech Inc. in 2005. Prior to XBiotech, he founded CTL ImmunoTherapies Corp. and AlleCure Corp., two companies that were merged in 2001 to form MannKind Corp. Simard has developed biological manufacturing at each of his Companies, including XBiotech’s manufacturing technology for monoclonal antibody production, which is currently providing contract manufacturing services for a world-leading pharma. Simard has and continues to pioneer therapies targeting interleukin-1a, recently selling a neutralizing antibody for cash and milestones of $1.35 billion. Simard received a degree in Biochemistry at the University of Saskatchewan in 1992 and went on to study immunology at the prestigious department of Medical Biophysics, University of Toronto. In 1994 Simard left the graduate program to work with acclaimed scientist Tak W. Mak at the Amgen Research Institute. Over the next several years, Simard wrote a textbook of immunology with Dr. Mak and co-authored numerous publications. During that time Simard also co-authored a seminal manuscript with Nobel Laureate Rolf Zinkernagel on the biology of cytotoxic T lymphocytes (CTL).